OBJECTIVES: As many as 50% of patients with severe symptomatic mitral valve regurgitation are denied surgical valve replacement or repair due to high operative risk. We describe an early series of cases of transcatheter implantation with a CardiAQ™ mitral valve via a transapical approach.
INTRODUCTION
Major advances have been made in catheter-based aortic [1] [2] [3] and pulmonary [4] [5] [6] [7] valve replacement over the past decade. The anatomy and typical calcific nature of aortic stenosis and right ventricular outflow tract conduit dysfunction are favourable to achieving stable anchoring of the prosthesis during transcatheter valve insertion. In contrast, the complex anatomy of the mitral valve (MV) has created a new set of challenges for catheter-based valve interventions in the mitral position. These challenges although real have now been surpassed, as a stable and a well-functioning mitral valve prosthesis implantation has been achieved in multiple acute and chronic animal models. However, challenges still remain before transforming this technology into clinical use.
Transcatheter mitral valve implantation (TMVI) offers a lesser invasive catheter-based therapy for mitral regurgitation (MR), which has a potential for being as effective as surgical mitral valve replacement. It also may address multiple types of MR and mitigate the challenges of varying morphologies of the disease. We describe below a small series of cases of transapical catheter-based chordal preserving mitral valve implantation with CardiAQ™ (CardiAQ Valve Technologies, Irvine, CA, USA) mitral valve.
MATERIALS AND METHODS

Valve prosthesis and delivery catheter
The CardiAQ™ prosthesis consists of a self-expanding nitinol frame, which has three leaflets of bovine pericardial tissue and is covered with a polytetrafluoroethylene membrane to minimize paravalvular leakage (Fig. 1) . The unique frame design features two sets of opposing anchors and allows for annular attachment without radial force. The frame engages and preserves the subvalvular apparatus of the native valve and features a 40 mm anchoring region and a 30 mm effective valve orifice region. The CardiAQ™ prosthesis was crimped and loaded into proprietary delivery system immediately before valve implantation. The delivery catheter system has several controls that gives the implanter infinite control in positioning and deploying the valve prosthesis.
The patients
CardiAQ TMVI was only considered in patients with symptomatic severe MR deemed unsuitable candidates for mitral valve surgery or transcatheter mitral valve repair by the MitraClip (Abbott Vascular, Santa Clara, CA, USA) procedure. All patients were assessed by the heart team and only accepted for TMVI based on the consensus that conventional surgical intervention posed excessive risk in terms of anticipated mortality and morbidity. Baseline patient characteristics are given in Table 1 . All patients gave their written informed consent and each case was approved by the Danish Health and Medicines Authority on compassionate grounds.
All patients underwent transoesophageal (TEE) echocardiography and cardiac multi-slice computer tomography (MSCT) with findings matched to predetermined inclusion and exclusion criteria to qualify for CardiAQ TMVI (Table 2) . Important anatomical considerations include the mitral annulus size with a diameter of <40 mm preferred to minimize the risk of paravalvular leak postimplantation, very acute aorto-mitral angle potentially increasing the risk of left ventricle outflow tract (LVOT) obstruction and the presence of sub-valvular apparatus calcification. Predicted fluoroscopic implant projections perpendicular to the MV annulus plane and angle of device implantation were also obtained from the MSCT data.
The procedure
Access to the left ventricle (LV) apex was gained through a left anterolateral mini-thoracotomy in the fifth intercostal space, with horizontal opening of the pericardium and placement of a retractor for exposure. Two teflon-reinforced box stitch sutures (Prolene 2-0) were then placed at the LV apex lateral to the left anterior descending coronary artery. In addition, a femoral arterial sheath was placed and a pigtail catheter inserted into the LV. Under fluoroscopic control, the LV apex was punctured and a soft J-tipped guide-wire passed retrogradely across the mitral valve. A 6 Fr sheath was inserted and the soft guide-wire was exchanged for an Amplatzer super-stiff guide-wire (Boston Scientific, Marlborough, MA, USA), which was placed into the right superior pulmonary vein, thereby crossing the mitral valve. A 46 mm Reliant balloon (Medtronic, Minneapolis, MN, USA) was then inserted into the LA, inflated with 5 ml of saline and retracted under fluoroscopy in order to make sure that the guide-wire was not caught in the chordae of the mitral valve (the Copenhagen manoeuvre). Next, the LV apex was further dilated with an 18 and 32 Fr dilator and the 32 Fr valve delivery system was inserted. The CardiAQ™ prosthesis was positioned and then deployed under fluoroscopic and echocardiographic guidance. The deployment sequence as seen on fluoroscopy is shown below in Fig. 2 . Confirmation of a well-positioned and well-functioning TMV prosthesis was obtained by periprocedural TEE (Fig. 3) .
The delivery system was retracted and the LV apex closed with box stitch sutures. A short period of cardiopulmonary bypass via femoral cannulation was used to help facilitate closure of the ventricular apex in Patient 1 and for haemodynamic support in Patient 3 who at baseline had severe impaired LV systolic function. The pericardium was left open, a chest tube inserted and the incision closed in a routine fashion.
RESULTS
Accurate positioning and deployment of the CardiAQ TMV was achieved in all the cases. MR was practically eliminated in all 3 patients. All 3 patients were extubated in the first 24 h. Two patients were discharged home, having improved significantly from their symptoms and have shown encouraging progress during their follow-up (Table 3) . Patient 3 died on postoperative day 9 due to severe hospital-acquired pneumonia. An autopsy was performed on the deceased patient with no prosthesis-related complications found. A summary of the results of all the patients and follow-up is given in Tables 3 and 4 . Cardiac computer tomography (CT) was performed to evaluate the position and anatomical status of the implant (Fig. 3) .
DISCUSSION
An analysis from the Euro Heart Study found that 49% of patients with symptomatic severe MR are not referred for surgery [8] . The authors found that decreased LVEF, non-ischaemic aetiology, older age, increased comorbidity and Grade 3 MR were independently associated with the decision not to operate. Cleveland Clinic patient database sought to determine the frequency and clinical outcomes of patients with severe MR and heart failure who do not undergo surgery [9] . Of 5737 patients with severe MR, 1095 had heart failure (74% functional MR and 26% degenerative MR). Mitral valve surgery was performed in 47% of patients and 577 (53%) patients were managed medically. Clinical outcomes were poor for unoperated patients with a 20% 1-year mortality rate and 50% 5-year mortality rate. Moreover, 90% of surviving patients were hospitalized for heart failure by 5 years, highlighting the tremendous unmet need for alternative management strategies in these high-risk patients. Although surgical treatment for primary MR has excellent outcomes, mitral valve surgery for secondary MR is associated with high operative mortality, frequent recurrence of MR and the lack of a clear survival advantage [10] [11] [12] [13] .
Mitral valve repair is a preferred approach for treating MR at this time. Surgical MV repair is exceedingly complex and best performed at expert, high-volume centres [14] where surgeons are adept at utilizing several techniques, including annuloplasty, leaflet resection, leaflet sliding plasty and placement of neochordae, among others, to essentially reconstruct the mitral valve. However, despite the application of this advanced armamentarium in an open heart under direct visualization of the valve, MR recurrence can be high with certain MV pathologies. A single transcatheter approach is therefore unlikely to challenge surgical MV repair and MR reduction.
In recent years, catheter-based mitral valve repair has shown promise. The EVEREST (Endovascular Valve Edge-to-Edge Repair Study) I and II studies established the safety, feasibility and efficacy of the MitraClip in reducing the severity of MR [15, 16] . On the other hand, despite encouraging early results, excitement for coronary sinus annuloplasty has waned as the limitations of the approach have become more apparent [17] [18] [19] [20] .
Transcatheter MV implantation may therefore provide a more tenable approach, especially in light of the favourable results obtained with surgical chordal-sparing MV replacement [21] . Transcatheter MV replacement is appealing in that it is anticipated to be low-risk and technically simpler than transcatheter repair, and can be utilized in high-risk patients and provide durable MR reduction and potentially a solution for multiple MR aetiologies [21, 22] . 
CONCLUSION
TMVI using a CardiAQ device is feasible in high-risk patients. Evolution of CardiAQ transcatheter valve technology has put TMVR within reach. Continued efforts focused on patient selection and a well-designed clinical trial should be undertaken to prove the clinical benefit of this technology.
Dr J.-F. Obadia (Lyon, France): The authors remind us that unoperated mitral valve diseases lead to catastrophic outcome, justifying a more active approach, even in patients who are not eligible for surgery. This is just a feasibility study 
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and it is already a success, since the 3 patients were extubated on day 1 with satisfactory haemodynamic results. I have three questions. First, I want you to comment on the absence of paravalvular leak, which is a main issue with all the other mitral valves that have already been implanted in the literature.
The second question concerns the absence of outflow tract obstruction. When you showed these 3-D images, we saw the valve which was partly implanted in the left atrium, but we also saw that you cut the anterior leaflet of the valve, and it was a little bit inside the outflow tract, and also on this very patient you had an angle with the septum which was very heavy. I'm a little bit surprised when you said in the paper that it was 10 mmHg. It's very low, this is the view. Here we expect an outflow tract obstruction, can you explain that?
The last question, in the paper you said that you had to do an apical approach, and in doing this apical approach, you used cardiopulmonary bypass, which surprised me, this is unusual.
Dr Holme: I'm going to answer the last one first. The first thing about the cardiopulmonary bypass, I have hidden it a little, but you discovered that we used it. It is not necessary for the implantation of the valve, actually, we need the filling of the heart and the movement of the heart when we relieve the valve. But when we had this very big introducer, which is a 33-Fr, through a thin ventricular muscle, we were very worried if we could close this hole on a full heart. When we had to close this apex, we put the patient on bypass for 5 minutes and closed the hole. In the future we hope that when the introducer goes down in size that we will not need this anymore. It was for the closure, to be sure.
Dr Obadia: It was just a decision you had made before, or did you have other patients before where you had a problem?
Dr Holme: No, no. We had some patients from the TAVI who had this problem, so we thought that it is better not to have that problem with this completely new procedure.
For the two other questions, I will refer them to Dr Quadri. He has more technical knowledge about the valve. I hope it's okay that he answers the questions.
Dr A. Quadri (Hartford, CT, USA): Your first question is regarding the minimum amount of paravalvular leak (PVL). The implant that we worked on has particularly addressed that issue in incorporating in the device a section which lies outside the stent, the frame of the valve, and because of the differential pressure between the atrium and the ventricle, it inflates and creates an adjustable seal to the mitral annulus. We particularly studied that issue in animals and we were able to eliminate it. Our first-generation valve experience showed us more than 1-plus MR, so we wanted to conquer that problem. That's all I can say about that. So it's a self-inflating, adjustable scenario that eliminates the MR. Does that satisfy your question?
Dr Obadia: Yes, of course. Dr Quadri: Now, the LVOT issue, learning from surgery, it is a major concern for any mitral intervention. We have recessed the implant; we basically recessed the ventricular approach to the implant.
That image shows that the anchors are definitely inside the LV outflow tract, but I want to point out that that anchor itself is only 2 mm wide, and there is flow around those anchors as you go. The distance between the bump and the hypertrophy of the septum, it is misleading to say that it is, because the leaflet itself is against the frame. It's recessed in. It's widely patent. So when you do the case and you see the images of the echo, there is turbulence, you will see some turbulence, and it looks like there should be. So we looked at it several times: Is there really no gradient? So that is what that is.
Dr A.P. Kappetein (Rotterdam, Netherlands): This new era of transcatheter mitral valve therapies is exciting. Are you not afraid that we are making the same mistake as we did with transcatheter aortic valve implantation where we choose the most difficult patients, the very old ones with many comorbidities? One additional risk factor that we face here is that patients also have a bad left ventricle. What do you think is the right exclusion criteria in terms of left ventricular function? We want to see not only the 30-day results but also the one-year results of this new therapy. I would like to get your opinion on this.
Dr Holme: These are the 3 patients we could find in Denmark that, on compassionate grounds, could have this done. It was not possible for us to get more normal patients, patients who were better than this. It would have been, of course, better for the outcome, especially EF. The patient who died had a very low EF, and that may be a problem.
Dr Kappetein: So what would be your advice? If you are going to start randomized studies or large registries, what would be the minimum level?
Dr Holme: High STS score and high EF, and that will be very difficult. I think the EF has to be higher than 20, but some of the other companies doing this have done it with low EF and some of the patients have done well, they also had some deaths. But yes, better EF, maybe about 30. Over that, it will be surely a better outcome.
Dr V. Subramanian (New York, NY, USA): I have just a very short comment. It's a concern for all the transcatheter mitral valve replacements. By design, you need to have a ventricular fixation by restraining the leaflet, native leaflet, between the anchors and the stented valve. Although you preserve anatomically, functionally you will interfere with the valvular-chordal-papillary muscle function. It's very important in a dilated ventricle because the papillary muscle complex still works. So you may end up with a diastolic filling problem. So you must measure the compliance of these bad ventricles going forward. As soon as the MR has gone away and the left atrial pressure comes down, you will have a problem in filling and heart failure will occur. I'm sure there is going to be a problem.
Dr M. Acker (Philadelphia, PA, USA): That is an interesting point, which, frankly, I have never thought about. But I have to say that when we do chordalsparing mitral valve replacement, we use a similar technique. We incorporate the chordae directly into the sewing ring. There is no flexibility there. So perhaps we are doing the same thing when we do it surgically.
Dr Subramanian: There are a lot of different preservation techniques. Most do supra-annular placement and a little bit of the leaflet near the rim, that's all. The function of the leaflet and the chordae and the papillary muscle is still good. If you go back and watch, there will be a concert, like an accordion. No matter what the ventricle is, the papillary muscle will move, the chordae will move, some of the leaflet will move, but if you strap that leaflet between the anchors, that is the mechanism by which you have to do it. Dr G. Bruschi (Milan, Italy): Do you think it's feasible to implant the valve via the right atrium and trans-septal, or directly via the left atrium through a right thoracotomy, so if you have any problem, you should go on pump and maybe do also a valve repair from the same access?
Dr Holme: This system is made for both transfemoral and trans-septal. We have done one patient. I have not brought it here today. We are working on both ways. Time will show what is best and what is most feasible.
